Selection of patients for cardiac resynchronisation therapy (CRT) in an unselected heart failure population

Insights

Many patients with chronic heart failure (CHF) qualify for cardiac resynchronisation therapy (CRT) based on current QRS width and ejection fraction criteria. Expanding criteria could identify more suitable candidates for CRT.

Area of Science:

  • Cardiology
  • Electrophysiology

Background:

  • Chronic heart failure (CHF) patients often exhibit myocardial conduction delay.
  • Cardiac resynchronisation therapy (CRT) is increasingly used for CHF.
  • Current CRT selection relies on left ventricular ejection fraction (LVEF) ≤35% and QRS widening, with or without left bundle branch block (LBBB).

Purpose of the Study:

  • To evaluate the proportion of CHF patients in a standard cardiology practice suitable for CRT.
  • To assess the impact of current and potential future criteria on CRT candidacy.

Main Methods:

  • Retrospective analysis of 861 CHF patients from January 2000 to December 2004.
  • Evaluation of LVEF, QRS width, and LBBB morphology.
  • Inclusion of patients with LVEF ≤35% and QRS width >120 msec or >140 msec.
  • Consideration of patients with LBBB and univentricular pacing devices.

Main Results:

  • 309 out of 861 CHF patients had LVEF ≤35%.
  • Among these, 123 had QRS width >120 msec and 81 had QRS width >140 msec.
  • 89 patients presented with LBBB morphology.

Conclusions:

  • A significant number of CHF patients meet current CRT eligibility criteria.
  • Potential exists to increase CRT candidate numbers by considering intraventricular conduction delay with less pronounced QRS widening, assessed via echocardiography.
Abstract

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
610
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
579
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
805
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
627
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K